scispace - formally typeset
Journal ArticleDOI

Anti-cancer drugs

Elke S. Bergmann-Leitner
- 31 Mar 2005 - 
- Vol. 14, Iss: 11, pp 1048-1048
Reads0
Chats0
About
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.

read more

Citations
More filters
Journal ArticleDOI

Rational design, synthesis, and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters.

TL;DR: The synthesis and the in vivo evaluation against leukemias P388 and L1210 of six new alkylating steroidal esters showed increased antileukemic activity and lower toxicity, compared to the 17beta-acetamido-7-keto analogs.
Journal ArticleDOI

A sulfoximine-based inhibitor of human asparagine synthetase kills l-asparaginase-resistant leukemia cells

TL;DR: The synthesis and biological activity of two new sulfoximine analogues of 1 are reported, providing further evidence for the idea that hASNS represents a chemotherapeutic target for the treatment of leukemia, and perhaps other cancers, including those of the prostate.
Journal ArticleDOI

Chlorophyll derivative mediated PDT versus methotrexate: an in vitro study using MCF-7 cells.

TL;DR: Compared to MTX, light activated chlorophyll derivative proved to be a better candidate for breast cancer cell toxicity, referring to its higher efficacy at tumour cells killing, safety to normal cells and simple method of extraction.
Journal ArticleDOI

Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib

TL;DR: The epidemiology, current treatment options and recent advances in the field are reviewed, with a focus on HER2-positive disease and the emerging role of lapatinib for the treatment and prevention of brain metastases.
References
More filters
Journal ArticleDOI

The status of platinum anticancer drugs in the clinic and in clinical trials.

TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI

Natural products to drugs: natural product derived compounds in clinical trials

TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI

Cellular distribution and functions of P2 receptor subtypes in different systems.

TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI

Natural products: an evolving role in future drug discovery.

TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.